KR101146095B1 - 1-(β-Ｄ-글루코피라노실)-4-메틸-3-〔5-(4-플루오로페닐)-2-티에닐메틸〕벤젠 반수화물의 결정형 - Google Patents

1-(β-Ｄ-글루코피라노실)-4-메틸-3-〔5-(4-플루오로페닐)-2-티에닐메틸〕벤젠 반수화물의 결정형 Download PDF

Info

Publication number
KR101146095B1
KR101146095B1 KR1020097013946A KR20097013946A KR101146095B1 KR 101146095 B1 KR101146095 B1 KR 101146095B1 KR 1020097013946 A KR1020097013946 A KR 1020097013946A KR 20097013946 A KR20097013946 A KR 20097013946A KR 101146095 B1 KR101146095 B1 KR 101146095B1
Authority
KR
South Korea
Prior art keywords
fluorophenyl
thienylmethyl
methyl
glucopyranosyl
benzene
Prior art date
Application number
KR1020097013946A
Other languages
English (en)
Korean (ko)
Other versions
KR20090086282A (ko
Inventor
스미히로 노무라
에이지 가와니시
Original Assignee
미쓰비시 타나베 파마 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38973167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101146095(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 미쓰비시 타나베 파마 코퍼레이션 filed Critical 미쓰비시 타나베 파마 코퍼레이션
Publication of KR20090086282A publication Critical patent/KR20090086282A/ko
Application granted granted Critical
Publication of KR101146095B1 publication Critical patent/KR101146095B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020097013946A 2006-12-04 2007-12-03 1-(β-Ｄ-글루코피라노실)-4-메틸-3-〔5-(4-플루오로페닐)-2-티에닐메틸〕벤젠 반수화물의 결정형 KR101146095B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86842606P 2006-12-04 2006-12-04
JPJP-P-2006-327019 2006-12-04
US60/868,426 2006-12-04
JP2006327019 2006-12-04
PCT/JP2007/073729 WO2008069327A1 (en) 2006-12-04 2007-12-03 CRYSTALLINE FORM OF 1- (β-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL] BENZENE HEMIHYDRATE

Publications (2)

Publication Number Publication Date
KR20090086282A KR20090086282A (ko) 2009-08-11
KR101146095B1 true KR101146095B1 (ko) 2012-05-16

Family

ID=38973167

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097013946A KR101146095B1 (ko) 2006-12-04 2007-12-03 1-(β-Ｄ-글루코피라노실)-4-메틸-3-〔5-(4-플루오로페닐)-2-티에닐메틸〕벤젠 반수화물의 결정형

Country Status (34)

Country Link
US (2) US7943582B2 (ja)
EP (1) EP2102224B2 (ja)
JP (1) JP5159788B2 (ja)
KR (1) KR101146095B1 (ja)
CN (3) CN102675380A (ja)
AR (3) AR064099A1 (ja)
AU (1) AU2007329895C1 (ja)
BR (1) BRPI0718882B8 (ja)
CA (1) CA2671357C (ja)
CL (1) CL2007003487A1 (ja)
CO (1) CO6210719A2 (ja)
CR (1) CR10861A (ja)
DK (1) DK2102224T4 (ja)
EA (1) EA017103B1 (ja)
EC (1) ECSP099489A (ja)
ES (1) ES2456640T5 (ja)
GT (1) GT200900151A (ja)
IL (1) IL199032A (ja)
ME (1) ME01829B (ja)
MX (1) MX2009005857A (ja)
MY (1) MY153702A (ja)
NO (1) NO344354B1 (ja)
NZ (1) NZ577545A (ja)
PA (1) PA8759401A1 (ja)
PE (3) PE20110841A1 (ja)
PL (1) PL2102224T5 (ja)
PT (1) PT2102224E (ja)
RS (1) RS53274B2 (ja)
SI (1) SI2102224T2 (ja)
SV (1) SV2009003285A (ja)
TW (1) TWI403325B (ja)
UY (1) UY30730A1 (ja)
WO (1) WO2008069327A1 (ja)
ZA (1) ZA200903941B (ja)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
ES2647504T3 (es) 2007-09-10 2017-12-21 Janssen Pharmaceutica N.V. Proceso para la preparación de compuestos útiles como inhibidores de SGLT
NZ591818A (en) 2008-08-22 2013-01-25 Theracos Inc Processes for the preparation of sglt2 inhibitors
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
WO2010092125A1 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102482250B (zh) 2009-07-10 2014-11-19 詹森药业有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的结晶方法
US8869918B2 (en) 2009-10-07 2014-10-28 Longyear Tm, Inc. Core drilling tools with external fluid pathways
CN102648196B (zh) * 2009-10-14 2016-04-27 詹森药业有限公司 可用作sglt2的抑制剂的化合物的制备方法
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
CN102115468B (zh) * 2009-12-31 2014-06-11 上海特化医药科技有限公司 一种2,5-二取代噻吩化合物的合成方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013523681A (ja) 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
CN106890147A (zh) 2010-05-11 2017-06-27 田边三菱制药株式会社 含1‑(β‑D‑吡喃葡糖基)‑3‑(苯基噻吩基甲基)苯化合物的片剂
CN108354930A (zh) * 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN102970981A (zh) 2010-07-06 2013-03-13 詹森药业有限公司 糖尿病协同治疗制剂
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US10544135B2 (en) * 2011-04-13 2020-01-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
JP5835598B2 (ja) 2011-06-03 2015-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 神経弛緩剤で治療されている患者において代謝性障害を治療するためのｓｇｌｔ−２阻害剤
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013038429A2 (en) 2011-09-13 2013-03-21 Panacea Biotec Ltd. Novel sglt inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
BR112014010574A2 (pt) 2011-10-31 2017-05-02 Scinopharm Taiwan Ltd formas cristalinas e não cristalinas de inibidores sglt2
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
CN103965267A (zh) * 2013-01-24 2014-08-06 江苏豪森医药集团连云港宏创医药有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯与L-苯丙氨酸共晶物及其制备方法
EP2968375B1 (en) 2013-03-14 2019-06-12 MSD International GmbH Methods for preparing sglt2 inhibitors
ES2647526T3 (es) 2013-03-15 2017-12-22 Janssen Pharmaceutica Nv Combinación de canagliflozina y probenecid para el tratamiento de la hiperuricemia
PL2981269T3 (pl) 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
US10323056B2 (en) 2013-05-08 2019-06-18 Lek Pharmaceuticals D.D. Crystalline hydrates of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
US20160083374A1 (en) 2013-05-30 2016-03-24 Cadila Healthcare Limited Amorphous form of canagliflozin and process for preparing thereof
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
CN103641822B (zh) * 2013-10-21 2016-06-08 江苏奥赛康药业股份有限公司 一种卡格列净化合物及其药物组合物
CN103588762A (zh) * 2013-11-27 2014-02-19 苏州晶云药物科技有限公司 坎格列净的新晶型及其制备方法
US20160280731A1 (en) * 2013-11-11 2016-09-29 Crystal Pharmatech Co., Ltd CRYSTALLINE FORMS B, C, and D OF CANAGLIFLOZIN
HUE053906T2 (hu) 2013-12-17 2021-07-28 Boehringer Ingelheim Vetmedica Gmbh SGLT2-inhibitorok macskafélék közé tartozó állatok anyagcsere-rendellenességeinek kezelésére
US10603300B2 (en) * 2014-01-23 2020-03-31 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in canine animals
WO2015116880A1 (en) 2014-01-31 2015-08-06 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders
US10174010B2 (en) 2014-03-19 2019-01-08 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
PT3125882T (pt) 2014-04-01 2020-08-17 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
CN103980262B (zh) * 2014-04-01 2016-06-22 天津大学 卡格列净的b晶型及其结晶制备方法
CN103980261B (zh) * 2014-04-01 2016-06-29 天津大学 卡格列净的a晶型及其结晶制备方法
CN103896930B (zh) * 2014-04-02 2016-08-17 安徽联创生物医药股份有限公司 卡格列净半水合物药用晶型的制备方法
EP2933255A1 (en) 2014-04-17 2015-10-21 LEK Pharmaceuticals d.d. Novel crystalline form of 1-(beta-D-glucopyranosyl)-4- methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
CN103936726B (zh) * 2014-04-18 2016-06-15 王军 晶体、制备方法及其用途
CN103936800A (zh) * 2014-05-08 2014-07-23 安徽联创药物化学有限公司 1-(1-甲氧基吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的制备方法
EP2947077A1 (en) 2014-05-19 2015-11-25 LEK Pharmaceuticals d.d. Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides
CN105330706B (zh) * 2014-06-05 2019-04-16 江苏豪森药业集团有限公司 卡格列净中间体的制备方法
CN105319294B (zh) * 2014-06-20 2021-03-30 重庆医药工业研究院有限责任公司 一种分离测定卡格列净及其有关物质的方法
CN104761546A (zh) * 2014-06-21 2015-07-08 山东富创医药科技有限公司 一种新颖的 (1s)-1,5-脱氢-1-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-d-葡萄糖醇晶型及其制备方法
WO2016016774A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited Crystalline forms of canagliflozin
EP2990029A1 (en) 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
US20170247359A1 (en) 2014-09-05 2017-08-31 Mylan Laboratories Ltd. Process for the preparation of canagliflozin
CZ2014634A3 (cs) 2014-09-16 2016-03-23 Zentiva, K.S. Komplexy canagliflozinu a cyklodextrinů
CN104402946B (zh) * 2014-11-17 2018-01-02 连云港恒运药业有限公司 卡格列净中间体及其无定形的制备方法
CN105753910A (zh) * 2014-12-16 2016-07-13 康普药业股份有限公司 一种卡格列净中间体的制备方法
CN108003149A (zh) * 2014-12-25 2018-05-08 重庆医药工业研究院有限责任公司 一种卡格列净晶型i及其制备方法
CN104945392A (zh) * 2015-01-27 2015-09-30 江苏嘉逸医药有限公司 结晶型卡格列净一水合物、制备方法及其应用
CN104530024B (zh) 2015-02-04 2017-08-08 上海迪赛诺药业有限公司 1‑(β‑D‑吡喃葡糖基)‑4‑甲基‑3‑[5‑(4‑氟苯基)‑2‑噻吩基甲基]苯的晶型及其制备方法
US10633372B2 (en) * 2015-02-27 2020-04-28 Msn Laboratories Private Limited Process for the preparation of amorphous (1S)-1,5-anhydro-1-[3-[[5-(4 fluorophenyl)-2-thienyl]-4-methylphenyl]-D-glucitol and its polymorphs thereof
JP2018087140A (ja) * 2015-02-27 2018-06-07 田辺三菱製薬株式会社 １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼンの新規結晶
WO2016142950A1 (en) * 2015-03-11 2016-09-15 Harman Finochem Limited A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form
US20180155329A1 (en) 2015-05-22 2018-06-07 Janssen Pharmaceutica Nv Anhydrous crystalline form of (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol
CN106279134A (zh) * 2015-06-23 2017-01-04 中美华世通生物医药科技（武汉）有限公司 卡格列净单晶及其制备方法和用途
CZ2015435A3 (cs) 2015-06-25 2017-01-04 Zentiva, K.S. Pevné formy amorfního canagliflozinu
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
ES2896101T3 (es) 2015-09-15 2022-02-23 Laurus Labs Ltd Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos
WO2017064679A1 (en) * 2015-10-15 2017-04-20 Lupin Limited Process for the preparation of amorphous canagliflozin
WO2017071813A1 (en) * 2015-10-30 2017-05-04 Zaklady Farmaceutyczne Polpharma Sa Process for the preparation of a pharmaceutical agent
CZ2015824A3 (cs) * 2015-11-20 2017-05-31 Zentiva, K.S. Krystalická forma Canagliflozinu a způsob její přípravy
EA036793B1 (ru) 2015-12-21 2020-12-22 Янссен Фармацевтика Нв Способ кристаллизации для получения кристаллов гемигидрата канаглифлозина
CN105541818A (zh) * 2016-03-04 2016-05-04 浙江华海药业股份有限公司 一种卡格列净水合物新晶型及其制备方法
CN107540706A (zh) * 2016-06-28 2018-01-05 山东诚创医药技术开发有限公司 伊格列净中间体的制备方法
WO2018020506A1 (en) 2016-07-25 2018-02-01 Natco Pharma Ltd Process for the preparation of amorphous form of canagliflozin
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
CN108017626A (zh) * 2016-11-04 2018-05-11 上海奥博生物医药技术有限公司 一种坎格列净半水合物新晶型
CN106588898A (zh) 2017-02-20 2017-04-26 浙江华海药业股份有限公司 一种卡格列净无定型的制备方法
BR112019026120A2 (pt) 2017-06-12 2020-07-07 Janssen Pharmaceutica N.V. métodos para reduzir ou prevenir eventos cardio-vasculares em pacientes com diabetes mellitus tipo ii
CN109553649B (zh) * 2017-09-26 2020-12-04 北大方正集团有限公司 一种卡格列净中间体的制备方法
AU2019254371A1 (en) 2018-04-17 2020-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
TW202103709A (zh) 2019-03-26 2021-02-01 比利時商健生藥品公司 用於治療患有慢性腎臟病之對象的方法
EP4064854A1 (en) 2019-11-28 2022-10-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors in the drying-off of non-human mammals
EP4106744A1 (en) 2020-02-17 2022-12-28 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
CN115916197A (zh) 2020-04-22 2023-04-04 拜耳公司 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合
CN113943329A (zh) * 2020-07-16 2022-01-18 尚科生物医药（上海）有限公司 一种坎格列净中间体的非对映异构体的制备方法
CN116249699A (zh) 2020-09-30 2023-06-09 北京睿创康泰医药研究院有限公司 一种sglt-2抑制剂·肌氨酸共晶体及其制备方法和应用
WO2023006718A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
EP4376830A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
WO2023227492A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012326A1 (en) 2003-08-01 2005-02-10 Tanabe Seiyaku Co., Ltd. Novel compounds having inhibitory activity against sodium-dependant transporter

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160861A (en) 1977-10-03 1979-07-10 Merck & Co., Inc. Method for the separation of antibiotic macrolides
US4584369A (en) 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
JP2544609B2 (ja) 1986-10-07 1996-10-16 和光純薬工業株式会社 Ｔｃｎｑ錯体
JP2786896B2 (ja) 1988-08-19 1998-08-13 ワーナー―ランバート・コンパニー 置換されたジヒドロイソキノリノンおよび関連化合物
JPH04253974A (ja) 1991-02-05 1992-09-09 Ishihara Sangyo Kaisha Ltd スルホニル尿素系化合物、それらの製造方法及びそれらを含有する除草剤
US5149838A (en) 1991-09-20 1992-09-22 Merck & Co., Inc. Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
GB9208161D0 (en) 1992-04-14 1992-05-27 Pfizer Ltd Indoles
US5334225A (en) 1992-07-15 1994-08-02 Kao Corporation Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler
US5731292A (en) 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US6297363B1 (en) 1993-02-12 2001-10-02 Nomura Co., Ltd. Glycoside indoles
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
US5780483A (en) 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
CA2236007A1 (en) 1995-10-31 1997-07-17 Gerald Floyd Smith Antithrombotic diamines
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JPH09263549A (ja) 1996-01-25 1997-10-07 Fujisawa Pharmaceut Co Ltd ベンゼン誘導体の製造法
ES2176600T3 (es) 1996-12-26 2002-12-01 Tanabe Seiyaku Co Derivado de la propiofenona y procedimientos para su preparacion.
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JPH10324632A (ja) 1997-03-25 1998-12-08 Takeda Chem Ind Ltd 医薬組成物
JP2000034239A (ja) 1998-07-16 2000-02-02 Asahi Glass Co Ltd トリフルオロメチル化芳香族化合物の製造方法
JP3857429B2 (ja) 1998-07-17 2006-12-13 ポーラ化成工業株式会社 含硫黄抗真菌剤
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
US6627611B2 (en) 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
AU3217501A (en) 2000-03-03 2001-09-12 Pfizer Prod Inc Pyrazole ether derivatives as anti-inflammatory/analgesic agents
NZ521369A (en) 2000-03-17 2004-07-30 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
DE60141156D1 (de) 2000-11-02 2010-03-11 Ajinomoto Kk Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
US6476352B2 (en) 2000-12-18 2002-11-05 General Electric Company Laser beam stop sensor and method for automatically detecting the presence of laser beam stop material using a laser beam stop sensor
EP1354888B1 (en) 2000-12-28 2009-05-20 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and use thereof in medicines
CA2438593C (en) 2001-02-26 2010-09-21 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
ES2350084T3 (es) 2001-02-27 2011-01-18 Kissei Pharmaceutical Co., Ltd. Derivados de glucopiranosiloxipirazol y uso médico de los mismos.
JP4190290B2 (ja) 2001-03-02 2008-12-03 ユニバーシティー オブ ウエスタン オンタリオ 放射能標識された化合物のポリマー前駆体、ならびにその作製および使用法
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ES2258141T3 (es) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
CA2445346C (en) 2001-04-27 2010-04-06 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
GB0112122D0 (en) 2001-05-18 2001-07-11 Lilly Co Eli Heteroaryloxy 3-substituted propanamines
CA2455300A1 (en) 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
WO2003011880A1 (fr) 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
ATE312940T1 (de) 2001-10-24 2005-12-15 Michael Burton Chromogenischen enzymsubstraten und verfahren zum nachweis von beta-d-ribofuranosidase-wirksamkeit
EA009281B1 (ru) 2001-11-16 2007-12-28 Катаникс Корпорейшн Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
US6617313B1 (en) 2002-03-13 2003-09-09 Council Of Scientific And Industrial Research Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof
US6562791B1 (en) 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
MXPA04010190A (es) 2002-04-18 2005-02-03 Astrazeneca Ab Compuestos heterociclicos.
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
EP1528066A4 (en) 2002-08-09 2007-05-02 Taisho Pharmaceutical Co Ltd ARYL-t-THIO-B-GLUCOPYRANOSIDE DERIVATIVES AND DIABETES CONTAINING THEM
WO2004018442A1 (en) 2002-08-23 2004-03-04 Dr. Reddy's Laboratories Limited Crystalline and amorphous forms of (s) -repaglinide and the processes for preparation thereof
JP4606876B2 (ja) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7375213B2 (en) 2003-01-03 2008-05-20 Bristol-Myers Squibb Company Methods of producing C-aryl glucoside SGLT2 inhibitors
WO2004080990A1 (ja) 2003-03-14 2004-09-23 Astellas Pharma Inc. Ｃ－グリコシド誘導体又はその塩
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
WO2004113359A1 (ja) 2003-06-20 2004-12-29 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
EP1679966A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv BENZIMIDAZOLE-, BENZTRIAZOLE- AND BENZIMIDAZOLONE-SUBSTITUTED O-GLUCOSIDES
US7129220B2 (en) 2003-08-01 2006-10-31 Janssen Pharmaceutica N.V Substituted indole-O-glucosides
EA010655B1 (ru) 2003-08-01 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индазол-о-глюкозиды
AR048376A1 (es) 2003-08-01 2006-04-26 Janssen Pharmaceutica Nv C- glicosidos heterociclos fusionados sustituidos
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
WO2005030127A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
ATE453656T1 (de) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US20090221592A1 (en) 2005-07-25 2009-09-03 Ellison Martha E Dodecylsulfate Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
WO2007054978A2 (en) 2005-11-10 2007-05-18 Jubilant Organosys Limited Process for preparing paroxetine hydrochloride hemihydrate
EP1842850A1 (en) 2006-03-23 2007-10-10 Sandoz AG Rosiglitazone hydrochloride hemihydrate
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
ES2647504T3 (es) † 2007-09-10 2017-12-21 Janssen Pharmaceutica N.V. Proceso para la preparación de compuestos útiles como inhibidores de SGLT

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012326A1 (en) 2003-08-01 2005-02-10 Tanabe Seiyaku Co., Ltd. Novel compounds having inhibitory activity against sodium-dependant transporter

Also Published As

Publication number Publication date
PE20081201A1 (es) 2008-09-04
DK2102224T4 (da) 2021-10-11
KR20090086282A (ko) 2009-08-11
EA200970540A1 (ru) 2009-10-30
AU2007329895B2 (en) 2011-09-08
JP5159788B2 (ja) 2013-03-13
PT2102224E (pt) 2014-04-07
US20110212905A1 (en) 2011-09-01
EP2102224B1 (en) 2014-02-12
SI2102224T2 (sl) 2021-11-30
NO344354B1 (no) 2019-11-11
NO20091778L (no) 2009-09-04
ZA200903941B (en) 2010-08-25
ME01829B (me) 2014-12-20
BRPI0718882B1 (pt) 2021-03-23
ES2456640T5 (es) 2021-12-02
AU2007329895A1 (en) 2008-06-12
AR064099A1 (es) 2009-03-11
CA2671357C (en) 2011-11-01
ES2456640T3 (es) 2014-04-23
PE20110841A1 (es) 2011-11-24
CO6210719A2 (es) 2010-10-20
GT200900151A (es) 2012-01-17
NZ577545A (en) 2011-08-26
CN102675380A (zh) 2012-09-19
SV2009003285A (es) 2010-08-17
CR10861A (es) 2009-07-17
DK2102224T3 (da) 2014-04-22
WO2008069327A1 (en) 2008-06-12
PL2102224T5 (pl) 2021-11-08
SI2102224T1 (sl) 2014-03-31
AR118450A2 (es) 2021-10-06
MX2009005857A (es) 2009-06-12
RS53274B2 (sr) 2021-10-29
US20080146515A1 (en) 2008-06-19
EA017103B1 (ru) 2012-09-28
TW200829259A (en) 2008-07-16
PA8759401A1 (es) 2009-04-23
AR107510A2 (es) 2018-05-09
CA2671357A1 (en) 2008-06-12
PL2102224T3 (pl) 2014-07-31
BRPI0718882B8 (pt) 2021-05-25
UY30730A1 (es) 2008-07-03
US7943582B2 (en) 2011-05-17
AU2007329895C1 (en) 2014-03-13
EP2102224A1 (en) 2009-09-23
BRPI0718882A2 (pt) 2014-09-16
MY153702A (en) 2015-03-13
ECSP099489A (es) 2009-08-28
CL2007003487A1 (es) 2008-03-14
US8513202B2 (en) 2013-08-20
EP2102224B2 (en) 2021-08-04
PE20130591A1 (es) 2013-05-12
CN101573368A (zh) 2009-11-04
CN102675299A (zh) 2012-09-19
IL199032A (en) 2012-12-31
RS53274B (en) 2014-08-29
JP2010511602A (ja) 2010-04-15
CN101573368B (zh) 2012-06-20
TWI403325B (zh) 2013-08-01

Similar Documents

Publication Publication Date Title
KR101146095B1 (ko) 1-(β-Ｄ-글루코피라노실)-4-메틸-3-〔5-(4-플루오로페닐)-2-티에닐메틸〕벤젠 반수화물의 결정형
RU2476438C2 (ru) Твердые формы макролидов
EP3511000B1 (en) Crystalline form x2 of grapiprant
WO2016136830A1 (ja) １－（β－Ｄ－グルコピラノシル）－４－メチル－３－［５－（４－フルオロフェニル）－２－チエニルメチル］ベンゼンの新規結晶

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
A101 Application to extend term of patent right by permit
J204 Request for invalidation trial [patent]
J204 Request for invalidation trial [patent]
J121 Written withdrawal of request for trial
J204 Request for invalidation trial [patent]
J121 Written withdrawal of request for trial
J501 Disposition of invalidation of trial
J121 Written withdrawal of request for trial
J501 Disposition of invalidation of trial
J501 Disposition of invalidation of trial
J121 Written withdrawal of request for trial
J206 Request for trial to confirm the scope of a patent right
J501 Disposition of invalidation of trial
J121 Written withdrawal of request for trial
J121 Written withdrawal of request for trial
J301 Trial decision

Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150701

Effective date: 20160216

J121 Written withdrawal of request for trial
FPAY Annual fee payment

Payment date: 20170420

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20180417

Year of fee payment: 7

J301 Trial decision

Free format text: TRIAL NUMBER: 2015100002325; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410

Effective date: 20180622

Free format text: TRIAL NUMBER: 2015100002305; TRIAL DECISION FOR INVALIDATION REQUESTED 20150409

Effective date: 20180622

Free format text: TRIAL NUMBER: 2015100002321; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410

Effective date: 20180622

Free format text: TRIAL NUMBER: 2015100002367; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410

Effective date: 20180622

G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20190417

Year of fee payment: 8